# Revolution Medicines, Inc.: filings

RVMD · Nasdaq · CIK 1628171 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rvmd.md) · [Financials](/companies/rvmd/financials.md) · [Filings](/companies/rvmd/filings.md) · [Insiders](/companies/rvmd/insiders.md)

## Reports and events: 111 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 373, 144 176, 8-K 71, SC 13G/A 30, 3 26, 10-Q 20, SC 13G 16, 424B5 13, SCHEDULE 13G/A 12, CORRESP 11, 425 9, 4/A 9, UPLOAD 9, DEFA14A 8, 10-K 7, S-8 7, SCHEDULE 13G 7, DEF 14A 6, ARS 4, EFFECT 4, 424B4 3, D 3, DRS 3, S-1 3, S-1/A 3, S-3ASR 3, 8-A12B 2, CERT 2, DRS/A 2, DRSLTR 2, FWP 2, SEC STAFF LETTER 2, 144/A 1, 305B2 1, 3/A 1, 424B3 1, 8-K/A 1, DEFM14A 1, S-1MEF 1, S-4 1, S-4/A 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 16:32 ET | [8-K](/filings/0001628171-26-000004.md) | 2.03 New direct financial obligation; 8.01 Other events | 0001628171-26-000004 |
| 2026-09-01 | 06:00 ET | [8-K](/filings/0001193125-26-377362.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-377362 |
| 2026-08-26 | 13:33 ET | [8-K](/filings/0001193125-26-366931.md) | 8.01 Other events | 0001193125-26-366931 |
| 2026-08-05 | 16:10 ET | [10-Q](/filings/0001193125-26-335104.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335104 |
| 2026-08-05 | 16:05 ET | [8-K](/filings/0001193125-26-335039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335039 |
| 2026-06-22 | 08:00 ET | [8-K](/filings/0001193125-26-276718.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-26-276718 |
| 2026-05-06 | 16:10 ET | [10-Q](/filings/0001193125-26-208969.md) | Quarterly report, period 2026-03-31 | 0001193125-26-208969 |
| 2026-05-06 | 16:05 ET | [8-K](/filings/0001193125-26-208918.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-208918 |
| 2026-04-27 | 17:30 ET | [DEF 14A](/filings/0001193125-26-182453.md) | Proxy statement, period 2026-06-18 | 0001193125-26-182453 |
| 2026-04-17 | 17:16 ET | [8-K](/filings/0001193125-26-161800.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-161800 |
| 2026-04-16 | 17:06 ET | [8-K](/filings/0001193125-26-159289.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-159289 |
| 2026-04-13 | 08:25 ET | [8-K](/filings/0001193125-26-152039.md) | 8.01 Other events | 0001193125-26-152039 |
| 2026-02-25 | 16:11 ET | [10-K](/filings/0001193125-26-071563.md) | Annual report, period 2025-12-31 | 0001193125-26-071563 |
| 2026-02-25 | 16:05 ET | [8-K](/filings/0001193125-26-071517.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071517 |
| 2025-11-05 | 16:10 ET | [10-Q](/filings/0001193125-25-266923.md) | Quarterly report, period 2025-09-30 | 0001193125-25-266923 |
| 2025-11-05 | 16:00 ET | [8-K](/filings/0001193125-25-266836.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-266836 |
| 2025-10-17 | 20:27 ET | [8-K](/filings/0001193125-25-241736.md) | 8.01 Other events | 0001193125-25-241736 |
| 2025-09-10 | 16:05 ET | [8-K](/filings/0001193125-25-200078.md) | 8.01 Other events | 0001193125-25-200078 |
| 2025-08-06 | 16:11 ET | [10-Q](/filings/0000950170-25-104022.md) | Quarterly report, period 2025-06-30 | 0000950170-25-104022 |
| 2025-08-06 | 16:05 ET | [8-K](/filings/0000950170-25-103983.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-103983 |
| 2025-06-27 | 16:05 ET | [8-K](/filings/0001193125-25-151254.md) | 5.07 Shareholder vote results | 0001193125-25-151254 |
| 2025-06-24 | 07:05 ET | [8-K](/filings/0001193125-25-145242.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-145242 |
| 2025-06-18 | 16:23 ET | [8-K](/filings/0001193125-25-142735.md) | 5.02 Departure or appointment of officers or directors | 0001193125-25-142735 |
| 2025-05-07 | 16:10 ET | [10-Q](/filings/0000950170-25-065660.md) | Quarterly report, period 2025-03-31 | 0000950170-25-065660 |
| 2025-05-07 | 16:05 ET | [8-K](/filings/0000950170-25-065618.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-065618 |
| 2025-04-29 | 16:38 ET | [DEF 14A](/filings/0001193125-25-103947.md) | Proxy statement, period 2025-06-26 | 0001193125-25-103947 |
| 2025-02-26 | 16:10 ET | [10-K](/filings/0000950170-25-027736.md) | Annual report, period 2024-12-31 | 0000950170-25-027736 |
| 2025-02-26 | 16:05 ET | [8-K](/filings/0000950170-25-027707.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-027707 |
| 2024-12-05 | 16:18 ET | [8-K](/filings/0001193125-24-271540.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-271540 |
| 2024-12-02 | 07:30 ET | [8-K](/filings/0001193125-24-268404.md) | 8.01 Other events | 0001193125-24-268404 |
| 2024-11-06 | 16:10 ET | [10-Q](/filings/0000950170-24-122303.md) | Quarterly report, period 2024-09-30 | 0000950170-24-122303 |
| 2024-11-06 | 16:05 ET | [8-K](/filings/0000950170-24-122266.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122266 |
| 2024-10-25 | 06:43 ET | [8-K](/filings/0001193125-24-243431.md) | 8.01 Other events | 0001193125-24-243431 |
| 2024-10-23 | 06:05 ET | [8-K](/filings/0001193125-24-241397.md) | 8.01 Other events | 0001193125-24-241397 |
| 2024-08-07 | 16:10 ET | [10-Q](/filings/0000950170-24-092783.md) | Quarterly report, period 2024-06-30 | 0000950170-24-092783 |
| 2024-08-07 | 16:05 ET | [8-K](/filings/0000950170-24-092735.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-24-092735 |
| 2024-07-15 | 08:03 ET | [8-K](/filings/0001193125-24-178836.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-178836 |
| 2024-06-24 | 16:06 ET | [8-K](/filings/0001193125-24-166939.md) | 5.07 Shareholder vote results | 0001193125-24-166939 |
| 2024-05-08 | 16:11 ET | [10-Q](/filings/0000950170-24-055655.md) | Quarterly report, period 2024-03-31 | 0000950170-24-055655 |
| 2024-05-08 | 16:05 ET | [8-K](/filings/0000950170-24-055606.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055606 |
| 2024-04-25 | 16:30 ET | [DEF 14A](/filings/0000950170-24-048380.md) | Proxy statement, period 2024-04-25 | 0000950170-24-048380 |
| 2024-02-26 | 16:08 ET | [10-K](/filings/0000950170-24-020145.md) | Annual report, period 2023-12-31 | 0000950170-24-020145 |
| 2024-02-26 | 16:04 ET | [8-K](/filings/0000950170-24-020125.md) | 2.02 Results of operations | 0000950170-24-020125 |
| 2024-01-09 | 14:15 ET | [8-K](/filings/0001193125-24-005061.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-005061 |
| 2023-12-26 | 17:45 ET | [8-K/A](/filings/0001193125-23-302252.md) | 9.01 Financial statements and exhibits | 0001193125-23-302252 |
| 2023-11-09 | 09:20 ET | [8-K](/filings/0001193125-23-274137.md) | 2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-274137 |
| 2023-11-06 | 16:09 ET | [10-Q](/filings/0000950170-23-059391.md) | Quarterly report, period 2023-09-30 | 0000950170-23-059391 |
| 2023-11-06 | 16:05 ET | [8-K](/filings/0000950170-23-059374.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-059374 |
| 2023-11-01 | 07:08 ET | [8-K](/filings/0001193125-23-267696.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-267696 |
| 2023-10-23 | 06:11 ET | [8-K](/filings/0001193125-23-260299.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-260299 |

Page 1 of 3. [Older](/companies/rvmd/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 12:38 ET. No prices; not investment advice.